HeraMED (ASX:HMD) - Stock Price, News & Analysis

HMD Stock Overview

Develops, manufactures, and sells heart beat monitors and other pregnancy monitoring solutions for home use in Australia, Europe, and Israel. More details

HMD fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Risk Analysis

Highly volatile share price over the past 3 months compared to the Australian market

Earnings have declined by 7.9% per year over past 5 years

Makes less than USD$1m in revenue (A$487K)

Shareholders have been substantially diluted in the past year

+ 1 more risk

HeraMED Limited Competitors

Control Bionics

ASX:CBL

AU$14.9m

InhaleRx

ASX:IRX

AU$7.4m

CardieX

ASX:CDX

AU$32.4m

Resonance Health

ASX:RHT

AU$24.4m

Price History & Performance

Summary of all time highs, changes and price drops for HeraMED
Historical stock prices
Current Share Price	AU$0.022
52 Week High	AU$0.045
52 Week Low	AU$0.012
Beta	0.084
11 Month Change	-12.00%
3 Month Change	29.41%
1 Year Change	-48.84%
33 Year Change	-92.90%
5 Year Change	-88.11%
Change since IPO	-87.78%

Recent updates

Shareholder Returns

	HMD	AU Medical Equipment	AU Market
7D	10.0%	0.5%	1.5%
1Y	-48.8%	14.2%	17.2%

Return vs Industry: HMD underperformed the Australian Medical Equipment industry which returned 14.2% over the past year.

Return vs Market: HMD underperformed the Australian Market which returned 17.2% over the past year.

Price Volatility

Is HMD's price volatile compared to industry and market?
HMD volatility
HMD Average Weekly Movement	18.0%
Medical Equipment Industry Average Movement	9.1%
Market Average Movement	8.6%
10% most volatile stocks in AU Market	17.3%
10% least volatile stocks in AU Market	3.4%

Stable Share Price: HMD's share price has been volatile over the past 3 months compared to the Australian market.

Volatility Over Time: HMD's weekly volatility (18%) has been stable over the past year, but is still higher than 75% of Australian stocks.

About the Company

Founded	Employees	CEO	Website
2011	n/a	Anoushka Gungadin	www.hera-med.com

HeraMED Limited, together with its subsidiaries, develops, manufactures, and sells heart beat monitors and other pregnancy monitoring solutions for home use in Australia, Europe, and Israel. It also provides HeraBEAT, a fetal heart rate monitor use by an expectant mother to monitor their fetus’ heartbeat; and HeraCARE, a cloud-based remote maternity care platform. The company has a collaboration agreement with Mayo Clinic for the development of its HeraCARE pregnancy management platform.

HeraMED Limited Fundamentals Summary

How do HeraMED's earnings and revenue compare to its market cap?
HMD fundamental statistics
Market cap	AU$13.93m
Earnings (TTM)	-AU$6.73m
Revenue (TTM)	AU$486.98k

28.6x

P/S Ratio

-2.1x

P/E Ratio

Is HMD overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
HMD income statement (TTM)
Revenue	AU$486.98k
Cost of Revenue	AU$268.47k
Gross Profit	AU$218.51k
Other Expenses	AU$6.94m
Earnings	-AU$6.73m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-0.011
Gross Margin	44.87%
Net Profit Margin	-1,381.03%
Debt/Equity Ratio	16.4%

How did HMD perform over the long term?

See historical performance and comparison

HMD Stock Overview

Risk Analysis

HeraMED Limited Competitors

ASX:CBL

AU$14.9m

ASX:IRX

AU$7.4m

ASX:CDX

AU$32.4m

ASX:RHT

AU$24.4m

Price History & Performance

Recent News & Updates

HeraMED Limited has completed a Follow-on Equity Offering in the amount of AUD 1.02 million.

HeraMED Limited has completed a Follow-on Equity Offering in the amount of AUD 3.1 million.

First half 2024 earnings released: AU$0.009 loss per share (vs AU$0.014 loss in 1H 2023)

New major risk - Shareholder dilution

New major risk - Shareholder dilution

HeraMED Limited, Annual General Meeting, May 30, 2024

Recent updates

HeraMED Limited has completed a Follow-on Equity Offering in the amount of AUD 1.02 million.

HeraMED Limited has completed a Follow-on Equity Offering in the amount of AUD 3.1 million.

First half 2024 earnings released: AU$0.009 loss per share (vs AU$0.014 loss in 1H 2023)

New major risk - Shareholder dilution

New major risk - Shareholder dilution

HeraMED Limited, Annual General Meeting, May 30, 2024

Heramed Limited Announces Board Changes

Full year 2023 earnings released: US$0.017 loss per share (vs US$0.023 loss in FY 2022)

HeraMED Limited, Annual General Meeting, Feb 23, 2024

HeraMED Limited has filed a Follow-on Equity Offering in the amount of AUD 1.285057 million.

HeraMED Limited Announces Emily Slade to Resign as Non-Executive Director

HeraMED Limited Limited Announces Resignation of David Groberman as Chief Executive Officer with Immediate Effect

HeraMED Limited Limited Announces Resignation of David Groberman as Chief Executive Officer with Immediate Effect

New minor risk - Share price stability

New major risk - Market cap size

Less than half of directors are independent

First half 2023 earnings released: US$0.009 loss per share (vs US$0.016 loss in 1H 2022)

HeraMED Limited, Annual General Meeting, Sep 19, 2023

HeraMED Limited has completed a Follow-on Equity Offering in the amount of AUD 2.58 million.

New major risk - Market cap size

Full year 2022 earnings released: EPS: US$0 (vs US$0.033 loss in FY 2021)

HeraMED Limited Announces Appointment of Keith Koby as President, North America

High number of new directors

HeraMED Limited has completed a Follow-on Equity Offering in the amount of AUD 4 million.

HeraMED Limited Appoints Emily Slade as Non-Executive Director

HeraMED Limited Appoints Emily Slade as Non-Executive Director

HeraMED Limited, Annual General Meeting, Oct 12, 2022

HeraMED Limited has completed a Follow-on Equity Offering in the amount of AUD 4 million.

First half 2022 earnings released: US$0.016 loss per share (vs US$0.01 loss in 1H 2021)

HMD Appoints Anoushka Gungadin as Director of Strategic Partnerships Australia and New Zealand

HeraMED Limited Announces Results of Sheba HeraBEAT Clinical Trial

Insufficient new directors

HeraMED Limited Announces Outstanding Results Achieved in Second Jhc Clinical Trial

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

High number of new directors

HeraMED Limited Provides Positive Interim Results US Paid Pilot & 2nd Site Confirmed

Full year 2020 earnings released: US$0.027 loss per share (vs US$0.035 loss in FY 2019)

HeraMED Limited has completed a Follow-on Equity Offering in the amount of AUD 2.332276 million.

HeraMED Limited Announces Sheba Medical Centre, Initiates Pilot to Test Both the HeraBEAT Device and HeraCARE Platform

Hapvida Extends its subscription for HeraCARE SaaS and cloud monitoring services for a further 24 months

HeraMED Limited Signs Letter of Intent with Teleperinatal

HeraMED Limited Announces Partnership with eCare21, Inc & Functional Integration Completed

Heramed Limited Announces Outstanding Clinical Study Results

HeraMED Limited Partnership with Leading Virtual Care Platform eCare21 in US

First half earnings released

HeraMED Limited announced that it expects to receive CAD 0.082999 million in funding

HeraMED Limited has completed a Follow-on Equity Offering in the amount of AUD 2.322419 million.

Shareholder Returns

Price Volatility

About the Company

HeraMED Limited Fundamentals Summary

28.6x

-2.1x

Earnings & Revenue